Anixa Biosciences Croissance future
Future contrôle des critères 0/6
Anixa Biosciences devrait augmenter ses bénéfices et ses revenus de 9.5% et de 75.2% par an respectivement, tandis que le BPA devrait croître de croître de 24.4% par an.
Informations clés
9.5%
Taux de croissance des bénéfices
24.4%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 27.1% |
Taux de croissance des recettes | 75.2% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 16 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate
Sep 12We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
May 23We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
10/31/2027 | N/A | -17 | -16 | -16 | 1 |
10/31/2026 | N/A | -16 | -16 | -16 | 1 |
10/31/2025 | N/A | -15 | -15 | -15 | 2 |
10/31/2024 | N/A | -13 | -46 | -11 | 2 |
7/31/2024 | N/A | -12 | -8 | -8 | N/A |
4/30/2024 | N/A | -12 | -7 | -7 | N/A |
1/31/2024 | 0 | -11 | -7 | -7 | N/A |
10/31/2023 | 0 | -10 | -6 | -6 | N/A |
7/31/2023 | 0 | -11 | -6 | -6 | N/A |
4/30/2023 | 0 | -11 | -6 | -6 | N/A |
1/31/2023 | N/A | -12 | -7 | -7 | N/A |
10/31/2022 | N/A | -14 | -6 | -6 | N/A |
7/31/2022 | 0 | -14 | -6 | -6 | N/A |
4/30/2022 | 0 | -16 | -6 | -6 | N/A |
1/31/2022 | 0 | -15 | -5 | -5 | N/A |
10/31/2021 | 1 | -13 | -5 | -5 | N/A |
7/31/2021 | 1 | -11 | -5 | -5 | N/A |
4/30/2021 | 1 | -9 | -5 | -5 | N/A |
1/31/2021 | 1 | -10 | -5 | -5 | N/A |
10/31/2020 | N/A | -10 | -6 | -6 | N/A |
7/31/2020 | N/A | -10 | -6 | -6 | N/A |
4/30/2020 | N/A | -9 | -5 | -5 | N/A |
1/31/2020 | 0 | -9 | -6 | -5 | N/A |
10/31/2019 | 0 | -12 | -5 | -5 | N/A |
7/31/2019 | 0 | -15 | -5 | -4 | N/A |
4/30/2019 | 1 | -18 | -5 | -5 | N/A |
1/31/2019 | 1 | -17 | -4 | -4 | N/A |
10/31/2018 | 1 | -14 | -4 | -4 | N/A |
7/31/2018 | 1 | -10 | -4 | -4 | N/A |
4/30/2018 | 1 | -7 | N/A | -4 | N/A |
1/31/2018 | 0 | -5 | N/A | -4 | N/A |
10/31/2017 | 0 | -7 | N/A | -4 | N/A |
7/31/2017 | 1 | -6 | N/A | -4 | N/A |
4/30/2017 | 0 | -6 | N/A | -3 | N/A |
1/31/2017 | 0 | -7 | N/A | -4 | N/A |
10/31/2016 | 0 | -5 | N/A | -3 | N/A |
7/31/2016 | 0 | -5 | N/A | -4 | N/A |
4/30/2016 | 0 | -6 | N/A | -3 | N/A |
1/31/2016 | 0 | -7 | N/A | -4 | N/A |
10/31/2015 | 0 | -1 | N/A | 1 | N/A |
7/31/2015 | 2 | -3 | N/A | 2 | N/A |
4/30/2015 | 3 | -1 | N/A | 2 | N/A |
1/31/2015 | 4 | -2 | N/A | 3 | N/A |
10/31/2014 | 4 | -10 | N/A | -2 | N/A |
7/31/2014 | 3 | -9 | N/A | -3 | N/A |
4/30/2014 | 1 | -12 | N/A | -3 | N/A |
1/31/2014 | 0 | -12 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ANIX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ANIX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ANIX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: ANIX ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: ANIX ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ANIX devrait être élevé dans 3 ans